These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29851957)

  • 1. KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.
    Rao DD; Luo X; Wang Z; Jay CM; Brunicardi FC; Maltese W; Manning L; Senzer N; Nemunaitis J
    PLoS One; 2018; 13(5):e0193644. PubMed ID: 29851957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
    Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
    Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant KRAS is a druggable target for pancreatic cancer.
    Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
    Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.
    Rachagani S; Senapati S; Chakraborty S; Ponnusamy MP; Kumar S; Smith LM; Jain M; Batra SK
    Br J Cancer; 2011 Mar; 104(6):1038-48. PubMed ID: 21364589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
    Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
    Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles.
    Zeng L; Li J; Li J; Zhang Q; Qian C; Wu W; Lin Z; Liang J; Chen Y; Huang K
    Pancreas; 2015 Mar; 44(2):250-9. PubMed ID: 25401377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth inhibition induced by short hairpin RNA to silence survivin gene in human pancreatic cancer cells.
    Shen YM; Yang XC; Song ML; Qin CH; Yang C; Sun YH
    Hepatobiliary Pancreat Dis Int; 2010 Feb; 9(1):69-77. PubMed ID: 20133233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
    Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
    Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.
    Pan T; Zhang Y; Zhou N; He X; Chen C; Liang L; Duan X; Lin Y; Wu K; Zhang H
    Oncotarget; 2016 Jul; 7(28):44299-44309. PubMed ID: 27322423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy.
    Werner K; Lademann F; Thepkaysone ML; Jahnke B; Aust DE; Kahlert C; Weber G; Weitz J; Grützmann R; Pilarsky C
    Oncotarget; 2016 Jan; 7(4):3984-92. PubMed ID: 26716649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
    Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
    Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer.
    Pei Y; Chen L; Huang Y; Wang J; Feng J; Xu M; Chen Y; Song Q; Jiang G; Gu X; Zhang Q; Gao X; Chen J
    Small; 2019 Jun; 15(24):e1900631. PubMed ID: 31033217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma.
    Wang Z; Zhang C; Nagee K; Mohammadi A; Monteiro C
    Pancreas; 2016 Mar; 45(3):337-41. PubMed ID: 26474433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.